AIV-007 is under clinical development by AiViva BioPharma and currently in Phase I for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase I drugs for Wet (Neovascular / Exudative) Macular Degeneration have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AIV-007’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AIV-007 overview

AIV-007 is under development for the treatment of neovascular age-related macular degeneration, macular edema and benign prostatic hyperplasia. It is administered by intravitreal and intraprostatic route. It targets vascular endothelial growth factor (VEGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR) and transforming growth factor-beta 1. The drug candidate is developed based on JEL technology.

AiViva BioPharma overview

AiViva BioPharma (AiViva) is a clinical-stage biotech company that develops drug products with the potential to profoundly reduce the treatment burden for patients and physicians and which may transform current treatment paradigms. AiViva is headquartered in Newport Beach, California, the US.

For a complete picture of AIV-007’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.